Monoclonal gammopathy of undetermined significance (MGUS) in patients with psoriasis may be associated with long-term treatment with efalizumab, but not with anti-TNF-α treatments or ustekinumab-Reference-Cited by-同舟云学术

Monoclonal gammopathy of undetermined significance (MGUS) in patients with psoriasis may be associated with long-term treatment with efalizumab, but not with anti-TNF-α treatments or ustekinumab

Published:2014-03-05 Issue:3 Volume:29 Page:609-611
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Vilarrasa E.¹,Puig L.¹

Affiliation:

1. Dermatology Department; Hospital de la Santa Creu i Sant Pau; Universitat Autonoma de Barcelona; Barcelona Spain

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.12409/fullpdf

Reference10 articles.

1. Development of MGUS in psoriatic patients: a possible undiagnosed event during anti-TNF-α-treatment;Prignano;J Eur Acad Dermatol Venereol,2012

2. Vilarrasa E Puig L Alomar A Monoclonal gammopathy of undetermined significance (MGUS) may be associated with long-term efalizumab treatment

3. Development of monoclonal gammopathy in 12 patients receiving efalizumab treatment for chronic plaque psoriasis;Prignano;J Am Acad Dermatol,2010

4. Prevalence of monoclonal gammopathy of undetermined significance;Kyle;N Engl J Med,2006

5. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression;Kyle;Br J Haematol,2007

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cryoglobulinemic Vasculitis Associated with Monoclonal Gammopathy of Undetermined Significance Developed after Sustained Virologic Response of Hepatitis C: A Case Report;Internal Medicine;2023

2. Monoclonal gammopathy of undetermined significance and biological treatments: What should we do?;Joint Bone Spine;2017-12

3. MGUS et traitements biologiques : que faire ?;Revue du Rhumatisme;2017-12